Nucleotides News and Research

RSS

Echevarne to distribute Natera's non-invasive prenatal screening test in Spain

Natera, a leading innovator in prenatal genetic testing, and Echevarne, a leading clinical analysis laboratory in Spain, today announced the signing of a distribution agreement for Echevarne to offer Natera's non-invasive prenatal screening test, Panorama, through its facilities in Spain.

From Natera 15 May 2013

Findings set the stage for identifying potential new drug targets, treatment strategies for AML

nvestigators for The Cancer Genome Atlas Research Network have detailed and broadly classified the genomic alterations that frequently underlie the development of acute myeloid leukemia, a deadly cancer of the blood and bone marrow.

2 May 2013

Details about genomic landscapes of AML and endometrial cancer revealed

Two studies from The Cancer Genome Atlas program reveal details about the genomic landscapes of acute myeloid leukemia and endometrial cancer.

2 May 2013

Researchers identify gene variations linked to male and female infertility

Identification of genetic variations in the genes coding for the hormone FSH may provide new treatments for male and female infertility, according to work presented at the European Congress of Endocrinology in Copenhagen.

30 Apr 2013

Berkeley Lab researchers unveil analytical technique for easy comparisons of proteins in solution

A revolutionary X-ray analytical technique that enables researchers at a glance to identify structural similarities and differences between multiple proteins under a variety of conditions has been developed by researchers with the U.S. Department of Energy's Lawrence Berkeley National Laboratory.

30 Apr 2013

New methods boost researchers' analytical powers by incorporating prior knowledge about SNPs function

As scientists probe and parse the genetic bases of what makes a human a human (or one human different from another), and vigorously push for greater use of whole genome sequencing, they find themselves increasingly threatened by the unthinkable: Too much data to make full sense of.

26 Apr 2013

Research on miRNAs offers new therapeutic potential to fight diseases

RNA molecules, made from DNA, are best known for their role in protein production. MicroRNAs (miRNAs), however, are short (~22) nucleotide RNA sequences found in plants and animals that do not encode proteins but act in gene regulation and, in the process, impact almost all biological processes - from development to physiology to stress response.

26 Apr 2013

Research supports polygenic phenotype in schizophrenia

Cumulative genetic risk for schizophrenia has been linked to impaired prefrontal brain activity, in findings that support an additive genetic risk model for a polygenic phenotype.

25 Apr 2013

Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

Gilead Sciences, Inc. today announced that detailed results from four Phase 3 clinical trials (NEUTRINO, FISSION, POSITRON and FUSION) evaluating sofosbuvir, the company's investigational once-daily nucleotide NS5B inhibitor for the treatment of chronic hepatitis C virus infection, will be presented this week in oral sessions at the 48th Annual Meeting of the European Association for the Study of the Liver in Amsterdam, The Netherlands.

23 Apr 2013

Study identifies potential drug targets that interfere with cancer metabolism

A massive study analyzing gene expression data from 22 tumor types has identified multiple metabolic expression changes associated with cancer.

22 Apr 2013

North American scientists chart new territory in immunity research

Cracking the DNA code for a complex region of the human genome has helped 14 North American scientists, including five at Simon Fraser University, chart new territory in immunity research.

19 Apr 2013

Preclinical studies show bladder cancers, mesotheliomas respond to treatment with ADI-PEG 20

Scientists from academic institutions reported at the 2013 annual American Association for Cancer Research meeting, results from preclinical studies which showed that certain bladder cancers and mesotheliomas have metabolic changes and are more likely to respond to treatment with ADI-PEG 20 (pegylated arginine deiminase) if they are deficient in the enzyme, argininosuccinate synthetase.

18 Apr 2013

Correcting prostate specific antigen levels for genetic variants can have significant consequences

Genetic variants have been identified which can increase serum prostate specific antigen concentrations and prostate cancer risk. A new study published in The Journal of Urology reports that correcting PSA levels for these genetic variants can have significant consequences, including avoiding unnecessary biopsies for some men and eliminating false complacency for others.

16 Apr 2013

Researchers find three new regions of genome that influence obesity in people of African descent

The largest genetic search for "obesity genes" in people of African ancestry has led to the discovery of three new regions of the human genome that influence obesity in these populations and others.

16 Apr 2013

Study shows genetic variant reduces pain severity associated with sexual assault

One in five U.S. women are sexually assaulted in their lifetimes and more than half experience severe pain during the week following an attack.

11 Apr 2013

Incidence of late-onset Alzheimer disease higher among African Americans

In a meta-analysis of data from nearly 6,000 African Americans, Alzheimer disease was significantly associated with a gene that have been weakly associated with Alzheimer disease in individuals of European ancestry, although additional studies are needed to determine risk estimates specific for African Americans, according to a study in the April 10 issue of JAMA, a Genomics theme issue.

11 Apr 2013

Gilead Sciences submits sofosbuvir NDA to FDA for treatment of chronic HCV infection

Gilead Sciences today announced that the company has submitted a New Drug Application to the U.S. Food and Drug Administration for approval of sofosbuvir, a once-daily oral nucleotide analogue for the treatment of chronic hepatitis C virus infection.

9 Apr 2013

Abstracts on Bristol-Myers Squibb's research in liver disease accepted for presentation

Bristol-Myers Squibb Company announced today that 14 abstracts on the Company's research in liver disease have been accepted for presentation at The International Liver CongressTM 2013, the 48th annual meeting of the European Association for the Study of the Liver, in Amsterdam, April 24 - 28.

8 Apr 2013

Vertex to conduct two Phase 2 studies of VX-135 in combination with daclatasvir

Vertex Pharmaceuticals Incorporated today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb Company to conduct Phase 2 studies of once-daily all-oral treatment regimens containing Vertex's nucleotide analogue hepatitis C virus polymerase inhibitor VX-135 and Bristol-Myers Squibb's NS5A replication complex inhibitor daclatasvir for the treatment of hepatitis C.

6 Apr 2013

Wistar scientists describe mechanics of oncogene-induced senescence

Researchers from The Wistar Institute explain a new molecular mechanism behind the phenomenon of oncogene-induced senescence. By depriving the cell of the ability to make new nucleotides-the building blocks of DNA molecules-cells can suppress cancer development by forcing a damaged cell into a senescent state, where the cell remains alive yet cannot reproduce.

5 Apr 2013